WHO fleshes out African and global lab capacity concerns
This article was originally published in Clinica
The WHO has acknowledged being concerned about the laboratory capacity of some countries in terms of meeting current influenza surveillance needs, saying that efforts to strengthen capacity are underway. "Surveillance is definitely not optimal everywhere in the world," said Keiji Fukuda, the WHO's interim assistant director-general for health security and the environment, during a press conference on July 7.
You may also be interested in...
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.
The first of around 260 patients for a clinical trial comparing its PB006 natalizumab biosimilar candidate to Biogen’s Tysabri reference brand have been recruited by Polpharma Biologics, which has just added Karsten Roth and Alexandra Moulson to its team.